Analyst Rating
based on 2 analysts
50.00%
Buy
50.00%
Hold
0.00%
Sell
Based on 2 analysts offering long term price targets for Emcure Pharmaceuticals Ltd. An average target of ₹1535
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd Share analysis
Emcure Pharmaceuticals Ltd price forecast by 2 analysts
Upside of8.83%
High
₹1600
Target
₹1535.00
Low
₹1470
Emcure Pharmaceuticals Ltd target price ₹1535, a slight upside of 8.83% compared to current price of ₹1405.25. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Emcure Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
Emcure Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:0
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,399.7₹1,443.4552 Week's Low
52 Week's High
₹1,225₹1,455.2
| Returns % | |
| 1 Month Return | + 12.84 % |
| 3 Month Return | + 3.77 % |
| 1 Year Return | + 3.77 % |
| Market Stats | |
| Previous Close | ₹1,410.45 |
| Open | ₹1,419.90 |
| Volume | 1.25L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹26,671.38Cr |
Key Statistics
| P/E Ratio | 70.64 |
| PEG Ratio | -6.19 |
| Market Cap | ₹324.46 Cr |
| P/B Ratio | 2.16 |
| EPS | 5.95 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 6.1 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹324.46 Cr | 159.01% | 0.66 | ₹5 Cr | ₹155 Cr | |
| BUY | ₹19,655.61 Cr | 54.71% | 0.57 | ₹397 Cr | ₹2,056 Cr | |
| NA | ₹97.84 Cr | 192.31% | 0.57 | NA | NA | |
| NA | ₹12.29 Cr | 57.71% | 0.50 | NA | NA | |
| NA | ₹911.24 Cr | 57.5% | 0.78 | ₹47 Cr | ₹1,207 Cr |
Mutual Fund Holdings
Company Information
Share Price: ₹1405.25 per share as on 05 Sep, 2024 04:01 PM
Market Capitalisation: ₹26,671.38Cr as of today
Revenue: ₹1,815.14Cr as on June 2024 (Q2 24)
Net Profit: ₹152.59Cr as on June 2024 (Q2 24)
Listing date: 10 Jul, 2024
| Organisation | Emcure Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Emcure Pharmaceuticals Ltd
Jefferies Initiates Buy Rating for Emcure Pharma - 26 Aug, 2024
Emcure Pharmaceuticals Ltd received its first Buy recommendation from Jefferies, targeting Rs 1,600. The firm highlights strong growth potential and minimal US market exposure.
Government Bans Combination Medicine by Emcure - 23 Aug, 2024
On August 12, the Health Ministry banned the manufacture, sale, and distribution of a fixed-dose combination medicine (Etodolac + Paracetamol) produced by Emcure Pharmaceuticals Ltd, impacting its market presence.
Emcure Reports Profit Growth Amid Regulatory Challenges - 14 Aug, 2024
Emcure Pharmaceuticals reported an 8.2% increase in net profit for Q1 FY25, with shares rising 2.5%. However, a government ban on a key product poses challenges ahead.
Emcure Pharmaceuticals Receives Credit Rating Upgrade - 13 Aug, 2024
Emcure Pharmaceuticals announced that CARE Ratings has upgraded its credit ratings for various bank facilities, reflecting improved financial stability and outlook.
Insights on Emcure Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, EMCURE stock has moved up by 2.5%
NO EFFECTFII Holding Unchanged
Foreign Institutions holdings remained unchanged at 1.76% of holdings in Jul 2024 quarter
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 16.82% of holdings in Jul 2024 quarter
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 78.08% of holdings in Jul 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 78.08% | 0.00 | |
| Foreign Institutions | 1.76% | 0.00 | |
| Mutual Funds | 1.77% | 0.00 | |
| Retail Investors | 16.82% | 0.00 | |
| Others | 1.57% | 0.00 |
Key Indicators
Earnings and Dividends
Emcure Pharmaceuticals Ltd Earnings Results
Emcure Pharmaceuticals Ltd’s net profit jumped 10.48% since last year same period to ₹144.08Cr in the Q1 2024-2025. On a quarterly growth basis, Emcure Pharmaceuticals Ltd has generated 25.1% jump in its net profits since last 3-months.
Read More about Earnings Results
Technicals Summary
Bearish
Neutral
Bullish
Emcure Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Emcure Pharmaceuticals Ltd shares.
Emcure Pharmaceuticals Ltd (EMCURE) share price today is ₹1405.25
Emcure Pharmaceuticals Ltd is listed on NSE
Emcure Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Emcure Pharmaceuticals Ltd is ₹1443.45.
- Today’s lowest price of Emcure Pharmaceuticals Ltd is ₹1399.7.
Today’s traded volume of Emcure Pharmaceuticals Ltd(EMCURE) is 1.25L.
Today’s market capitalisation of Emcure Pharmaceuticals Ltd(EMCURE) is ₹26671.38Cr.
| Emcure Pharmaceuticals Ltd(EMCURE | Price |
|---|---|
52 Week High | ₹1455.2 |
52 Week Low | ₹1225 |
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1405.25. It is down -3.43% from its 52 Week High price of ₹1455.2
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1405.25. It is up 14.71% from its 52 Week Low price of ₹1225
| Emcure Pharmaceuticals Ltd(EMCURE | Returns |
|---|---|
1 Day Returns | -5.2% |
1 Month Returns | 12.84% |
3 Month Returns | 3.77% |
1 Year Returns | 3.77% |